Advanced Filters
noise

Uterine Cancer Clinical Trials

A listing of Uterine Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 218 clinical trials
J Jalal Prasun

Safety Evaluation of Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis

This is a single center, randomized, parallel assignment, and double-blind placebo-controlled pilot study to characterize the intestinal microbiome in patients with severe Alcoholic Hepatitis (SAH) and evaluate the safety and the trends in improvement of diversity of intestinal microbiome following administration of lyophilized capsules containing microbiota suspension from well screened …

18 - 75 years of age All Phase 1/2
L Lindsey Hiebert

The Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry

Clinical interventions to reduce the risk of vertical transmission of hepatitis C virus (HCV) infection from mother to infant are highly limited. Direct-acting antiviral (DAA) medications have demonstrated excellent safety and efficacy in non-pregnant individuals, but there is a lack of data regarding the safety of these medications in pregnant …

years of age All Phase N/A
F For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B

Background Chronic hepatitis B virus (HBV) infection affects 292 million people worldwide; 887,000 die each year from cirrhosis, liver cancer, and related issues. Treatment options are limited. Objective To test 2 drugs (VIR-2218 and peginterferon) in people with mild or inactive HBV infection. Eligibility People aged 18 to 65 years …

18 - 65 years of age All Phase 2
L Linghua Li, PhD

Functional Cure of Hepatitis B in HIV/HBV Co-infected Patients

Evaluate the potential of ART combined with interferon therapy to achieve functional cure of hepatitis B in HIV/HBV co-infected patients

18 - 65 years of age All Phase N/A
T Teng-Yu Lee, MD, PhD

Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B

To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir (ETV) in the chronic hepatitis B patients.

20 years of age All Phase 4
C Carol Boxtha

Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening

This innovative Multilevel Action Toward Colorectal Cancer (CRC) and Hepatitis C Virus (HCV) Education and Screening (MATCHES) intervention aims to promote concurrent HCV and CRC screening among FQHC patients ages 45-75.

45 - 75 years of age All Phase N/A
A Andreas M Schmitt, MD

Management of Immune Checkpoint Inhibition-related Hepatitis Using Low-dose Corticosteroids

This study evaluates the effectiveness of low-dose corticosteroids in managing grade 2-3 immune-related hepatitis in cancer patients treated with immune checkpoint inhibitors. It aims to determine whether of 0.5-1miligram per kilogram bodyweight prednisolone is sufficient to manage immune-related hepatitis without the need for dose escalation or additional immunosuppressive therapy.

18 years of age All Phase N/A

Specific Biomarkers of Immune-mediated Hepatitis Secondary to Immune Checkpoint Inhibitors

Identify specific blood biomarkers for hepatitis induced by immune checkpoint inhibitors in comparison to idiopathic autoimmune hepatitis.

18 years of age All Phase N/A
C CHYI-FENG JAN, MD, PhD

The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort

This prospective cohort study aims to provide the evidence-based clinical guide to help decide the revaccination doses of hepatitis B vaccine that the high-risk young adults without hepatitis B seroprotective antibodies (anti-HBs titer\<10 mIU/mL) need to take.

20 - 36 years of age All Phase N/A
M Moana GELU-SIMEON

Is Negativity of Autoantibodies a Marker of Severity in Auto-immune Hepatitis?

Evaluate the proportion of seronegative auto-immune hepatitis and a possible relationship with the severity of the disease. Criteria of severity will be defined by corticodependance, corticoresistance and a severe form of the disease at diagnosis (cirrhosis or fulminant hepatitis). In case of predominant seronegative forms, other auto-antibodies related to this …

18 years of age All Phase N/A

Simplify language using AI